News Daily News AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients Michael O'Riordan August 26, 2024
News Conference News ESC 2023 ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More Michael O'Riordan September 06, 2023
News Conference News ESC 2023 FIRE: Complete Revascularization Best Even for Elderly Patients With MI Michael O'Riordan August 26, 2023
News Conference News SCAI 2023 Repeat Revascularization Not Increased With Solo Ticagrelor: TWILIGHT Analysis L.A. McKeown May 22, 2023
News Daily News Medical Devices Cleared on Faulty Predicates More Likely to be Recalled Michael O'Riordan January 17, 2023
News Daily News P2Y12 Inhibitors Top Aspirin Following Post-PCI DAPT: Network Meta-analysis Todd Neale November 21, 2022
News Daily News Single-Center Study Offers Insights for Ticagrelor vs Prasugrel in Chronic CAD Yael L. Maxwell November 21, 2022
News Conference News TCT 2022 New Faces, New Formats, New Tech: What to Expect From TCT 2022 Shelley Wood September 07, 2022
News Conference News ESC 2022 Polypill Bests Usual Care in Patients With Recent MI: SECURE Michael O'Riordan August 26, 2022
News Daily News Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy L.A. McKeown June 01, 2022
News Conference News ACC 2022 No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3 Michael O'Riordan April 13, 2022
News Features FFR’s Future: Negative Trials Spur Debate Over Technology’s Role Michael O'Riordan December 23, 2021
News Features Expired Cardiac Devices May Do Global Good, but Safety Unknown Yael L. Maxwell August 26, 2021
News Daily News Vascular Experts Say It’s Time to Let Paclitaxel Out of Regulatory Jail L.A. McKeown April 22, 2021
News Daily News Site Investigators Missed Clinical Events in GLOBAL LEADERS Michael O'Riordan February 12, 2021
News Daily News ‘Aspirin-Free’ Antiplatelet Strategy Feasible After PCI, Pilot Study Suggests Michael O'Riordan September 18, 2020
News Daily News PCI Volumes Rise in US and Japan, but for Different Reasons Michael O'Riordan September 14, 2020
News Industry News CeloNova Announces Enrollment Completion of World’s First Randomized Control, 14-Day DAPT Trial June 01, 2020